1261491-89-7

Basic information

• Product Name: Olumacostat Glasaretil
• Synonyms: Olumacostat Glasaretil
• CAS NO: 1261491-89-7
• Molecular Formula: C26H43NO7
• Molecular Weight: 481.62212
• EINECS: -0
• Mol File: 1261491-89-7.mol

Chemical Properties

• Boiling Point: 583.9±50.0 °C(Predicted)
• Appearance: /
• Density: 1.057±0.06 g/cm3(Predicted)
• PKA: -1.44±0.70(Predicted)
• CAS DataBase Reference: Olumacostat Glasaretil(CAS DataBase Reference)
• NIST Chemistry Reference: Olumacostat Glasaretil(1261491-89-7)
• EPA Substance Registry System: Olumacostat Glasaretil(1261491-89-7)

Safety Data

• Hazardous Substances Data: 1261491-89-7(Hazardous Substances Data)

Usage

Uses

Used in Dermatological Applications:
Olumacostat Glasaretil is used as a therapeutic agent for the treatment of acne and oily skin. It targets the enzyme acetyl-CoA carboxylase (ACC1) involved in sebum production, thereby reducing excess sebum and alleviating the symptoms of these skin conditions.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Olumacostat Glasaretil is utilized as a selective inhibitor of ACC1 for the development of novel treatments targeting skin conditions related to sebum overproduction. Its targeted approach offers a potential alternative to broader systemic interventions, potentially reducing side effects and improving patient outcomes.

Upstream product

• 24515-53-5 [(2-chloroacetyl)(methyl)amino]acetic acid ethyl ester 
• 54857-86-2 5-(tetradecyloxy)-2-furancarboxylic acid 

Relevant articles and documents

DERMATOLOGICAL FORMULATIONS OF 2-(2-ETHOXY-2-OXOETHYL)(METHYL)AMINO-2-OXOETHYL 5-(TETRADECYLOXY)FURAN-2-CARBOXYLATE

Disclosed herein are dermatological formulations comprising low-impurity TOFA prodrug 2-(2-ethoxy-2-oxoethyl)(methyl)amino-2-oxoethyl 5-(tetradecyloxy)furan-2-carboxylate represented by Formula (la) and pharmaceutical use thereof.

Olumacostat glasaretil

Acne vulgaris is a common dermatologic condition affecting adolescents and adults. Systemic and topical therapies have been developed to target different mechanisms in the pathogenesis of acne. Olumacostat glasaretil (OG) is a novel topical agent that targets sebum production in the treatment of acne vulgaris. OG’s active metabolite acts as a competitive inhibitor of the rate-limiting enzyme of fatty acid synthesis, acetyl-coenzyme A (CoA) carboxylase (ACC). ACC catalyzes malonyl-CoA formation and sebum production. OG is efficacious in the treatment of acne vulgaris and has a low side effect profile. Phase IIa and IIb trials note side effects including application-site erythema and dryness, and nasopharyngitis. Phase III trials are currently underway. The new mechanism of action of OG is sensible, attractive and exciting, but the available data do not demonstrate that it provides a quantum leap forward over existing therapies.

SYNTHETIC PROCESS FOR PREPARING 2-((2-ETHOXY-2-OXOETHYL)(METHYL)AMINO)-2-OXOETHYL 5-TETRADECYLOXY)FURAN-2-CARBOXYLATE

Disclosed herein are processes for forming 2-((2-ethoxy-2-oxoethyl)(methyl)amino)-2-oxoethyl 5-tetradecyloxy)furan-2-carboxylate:

TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS

This invention is directed to analogs of 5-(tetradecyloxy)-2-furancarboxylic acid (TOFA) and their use in the treatment of dermatological disorders or conditions characterized by sebaceous gland hyperactivity, such as acne and oily skin, and other dermato